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ABSTRACT OF THESIS 
 
 
 
 
REFERENCE POINT INDENTATION OF HUMAN TRABECULAR BONE 
TREATED WITH BISPHOSPHONATES FOR VARYING DURATIONS 
 
 
Reference point indentation (RPI), a novel form of micro-indentation, quantifies 
RPI material parameters which correlate with modulus, yield stress, strength, or 
toughness.  Information linking bisphosphonate treatment length with the material 
properties of osteoporotic trabecular bone is needed to improve patient treatment.  The 
objectives of this study were to: 1) determine if RPI can be used to successfully evaluate 
human trabecular bone and if so, determine an optimized test method for using RPI on 
trabecular bone, and 2) use this method to determine if any RPI parameters are related to 
the duration of bisphosphonate treatment. 
Indentation using a 4 N applied force for 5 cycles was determined to be optimal 
and used to indent trabecular bone samples from 44 post-menopausal, osteoporotic 
female patients treated with bisphosphonates for varying (0.8 to 14 years) durations. 
Considering patient age and calcium supplementation use as covariates, six RPI 
parameters were significantly (p<0.05) related to BP treatment duration.  These results 
show that the duration of BP treatment is associated with declining RPI-parameters in 
human trabecular bone.  Given prior findings linking these RPI parameters with 
established material parameters, the present findings suggest that increasing duration of 
BP treatment is associated with declining trabecular bone material properties.    
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1 Introduction 
1.1 Bone 
Bone is a composite material consisting of mineralized calcium, collagen fibers, 
water, and other proteins [1].  This mineralized form of calcium, known as 
hydroxyapatite, forms around collagen fibers [1].  Hydroxyapatite crystals grow in the 
same orientation as collagen fibers; this contributes to the anisotropic material properties 
of bone [1].  Mineralization provides strength and stiffness to bone while collagen 
provides flexibility and energy absorption [2]. 
The relative amounts of mineral and matrix in bone, commonly measured by the 
mineral/matrix ratio by using a variety of spectroscopic techniques, has a significant 
effect on the bone’s elastic modulus, strength, and toughness (Figure 1.1) [2].  Hyper-
mineralized bone has a higher elastic modulus but reduced toughness [2].  Hypo-
mineralized bone has an increased toughness, a lower modulus, and an intermediate 
strength [2].  
 
Figure 1.1 Bone Material Properties with Varying Mineralization 
 
There are two distinctive types of human bone (Figure 1.2).  Trabecular bone is a 
mesh-like network of thin, calcified tissue strands.  Cortical bone is a thick, dense layer 
of calcified tissue formed as the outer shell of bone.  Only 15-25% of trabecular bone is 
calcified while cortical bone is 80-90% calcified [1].  Both types have important load 
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bearing roles, but trabecular bone’s high surface area to volume ratio also serves a 
significant role in calcium homeostasis [1].   
 
Figure 1.2  Parts of Bone 
1.2 Osteoporosis 
Osteoporosis is a bone disease characterized by an above-average increase in 
normal bone porosity and a below-average reduction in bone mineral density (BMD) [3]. 
This disease commonly occurs in post-menopausal Caucasian women due to an estrogen-
deficient related increase in bone turnover and subsequent decrease in bone 
mineralization [4].  Estrogen modulates bone resorption by inducing osteoclast apoptosis 
and suppressing osteoclastogenic cytokine production [3].  Lower estrogen levels allow 
for increased osteoclast activity which results in increased turnover, hypomineralization, 
and mechanically disadvantageous microstructural characteristics such as fewer, thinner, 
and less well connected trabeculae (Figure 1.3).   
Osteoporosis is diagnosed by measuring lumbar spine and proximal hip BMD 
using dual-energy x-ray absorptiometry [5].  The World Health Organization’s criteria for 
osteoporosis is that if either hip or spine BMD is more than 2.5 standard deviations below 
the gender-specific population average BMD, then the patient is considered osteoporotic 
[5].   
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Osteoporosis is a major health problem because of the loss of adequate bone 
strength that occurs due to increased porosity, decreased cortical thickness, reduced 
trabecular bone structural parameters, and adverse material property changes that 
collectively render bone unable to withstand normal physiologically imposed loading.  
These structural and compositional changes to bone decrease the extrinsic strength of 
bone and have shown a stronger correlation with patient fracture risk than BMD [5] [6] 
[7] [8] [9].   
 
Figure 1.3 Healthy vs Osteoporotic Trabecular Bone 
1.3 Osteoporosis Prevalence  
Fractures are the most serious complication of osteoporosis [10].  Most 
osteoporotic fractures occur in the hip or spine and can result in permanent disability or 
initiate a sequence of downward-spiraling events that culminate in death [10]. An 
increasing number of women with post-menopausal osteoporosis, and the ensuing 
compromises to life quality as well as healthcare costs due to osteoporosis-related 
fractures, underscore the need for effective treatments.  An estimated 10 million 
Americans were osteoporotic and an additional 34 million had low bone mass in 2011 
[11]. Healthcare costs due to osteoporosis treatment and osteoporotic fractures were 
estimated to be $22 billion in 2008 alone [12].  These costs will grow because the number 
of Americans with osteoporosis is expected to increase to more than 14 million by 2020 
[11] [12] [4].   
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1.4 Treatments for Osteoporosis 
Traditional therapies for reducing bone loss and fracture risk attributable to 
osteoporosis include monitoring calcium and vitamin D intake and appropriate physical 
exercise [13].  A variety of pharmacologic osteoporosis treatments are also routinely 
prescribed, but their benefits are under question [14]. Oral bisphosphonates are the most 
common pharmacologic treatment for osteoporosis with more than 30 million actively 
treated patients worldwide in 2006 alone [15].   
1.5 Bisphosphonates                                                                                                                                                                                                                                                                                      
The increase in resorption due to cessation of estrogen production in post-
menopausal osteoporosis can be offset by stimulating bone formation or decreasing bone 
resorption.  Bisphosphonates suppress bone resorption [16].   Their chemical structure, 
which resembles pyrophosphate (Figure 1.4) confers them with a high affinity for 
exposed hydroxyapatite crystals in active remodeling sites.  Once resorbed by osteoclasts, 
bisphosphonates induce osteoclastic apoptosis which in turn results in reduced 
osteoclastic activity [17]. 
 
Figure 1.4 Bisphosphonate and Pyrophosphate Structure 
Extended periods of reduced osteoclast activity resulting from long term 
bisphosphonate treatment are known to reduce the rate of bone turnover.  Reduced bone 
turnover allows old and damaged bone to accumulate [17].  This in turn results in 
impaired load-bearing mechanical competence of such bone, and this in turn renders bone 
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more susceptible to fracture than bone with normal turnover [18].  Disagreement exists 
regarding the consequences of increased fracture risk and the benefits of long-term 
bisphosphonate treatment.  Some believe the estimated 1 in 1,000 risk of long-term 
bisphosphonate related atypical femoral fractures is overshadowed by the overall fracture 
reducing benefits of the bisphosphonates [19].   Others speculate that 100 osteoporosis-
related fractures are prevented for every atypical fracture related to bisphosphonate 
treatment [20].  Some suggest discontinuing bisphosphonate use if bone mineral density 
levels are adequate [20].   
1.6 Material Property Assessment 
There are well established methods for determining the material properties of bone 
[21].  Macroscopic load to failure testing is the current gold standard for quantifying the 
bone material properties.  Surrogate testing methods with technological advantages have 
been created and among these is nanoindentation, a spin-off of Atomic Force 
Microscopy.  This method has recently emerged as a useful technique for non-destructive 
measurement of Young’s modulus and hardness of bone with great spatial resolution 
[21].   
The applied force and resulting displacements obtained from nanoindentation 
testing are recorded from a diamond indenter tip as it is forcibly pressed deeper into a 
polished flat surface of the material being tested [21].  A portion of the force-
displacement unloading slope (Figure 1.5) is used to calculate material modulus by using 
a model developed by Oliver and Pharr and as quantified in  
Equation 1 and Equation 2 [22] [23].   
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Figure 1.5 Ideal Nanoindentation Load-Displacement Cycle 
These calculations assume a flat, polished indenting surface, zero frictional forces, 
and a material that is linear elastic and incompressible [24] [22].  Calculation of the 
projected contact area between the probe and indentation surface is based upon the 
known geometry of the probe and its penetration depth.   
Equation 1: Nanoindentation Reduced Modulus 
 
Er:  Reduced modulus  
hc, β:  Geometric constants 
Ap(hc):  Projected area of the indentation at the contact depth 
S:  Stiffness of contact (unloading slope) 
 
Equation 2: Nanoindentation Material Modulus 
 
 
Ei:  Known indentation probe modulus 
Es: Modulus of material 
νi:  Poisson’s ratio of probe  
νs: Poisson’s ratio of material 
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Nanoindentation indent widths can range from 10 to 1000 nanometers which allows 
a high degree of location specificity.  Material properties of bone measured by 
nanoindentation vary between individuals and specific bones [25] [26].  Variability is 
also dependent upon indent location and lamellar orientation within the same bone [27] 
[28] [29].   
1.7 Reference Point Indentation 
Microindentation techniques load materials in a similar manner to nanoindentation 
but utilizes larger probe dimensions, greater penetration depths (30-200 microns vs. 10-
1000 nanometers), and greater indentation widths (Figure 1.6).  Because of the greater 
size microindentation probes, this technique is influenced by bone porosity, multiple 
lamellae layers, interfaces between structural units, and microdamage [30].   
 
Figure 1.6: Nanoindentation vs RPI Depth in a Trabeculum 
 RPI instrumentation systems typically include a measurement head unit, 
measurement stand, and probe assembly (Figure 1.7).  The measurement head unit 
contains a force generator, force sensor, and displacement sensor.  The measurement 
stand enables accurate probe-on-sample positioning by using via an XY translational 
table to place the indentation probe tip at the desired location.  The probe assembly 
consists of two coaxial components; an indenting test probe that moves coaxially within a 
reference probe (Figure 1.8). The test probe consists of a 375 micron diameter rod with a 
90 degree coned tip having a radius of less than 5 microns [31].  The reference probe 
consists of a hollow tube (fabricated from a modified hypodermic needle) that coaxially 
contains the test probe.     
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Figure 1.7 Reference Point Indentation Device 
 
Figure 1.8 Reference Point Indentation Probe Illustration 
Reference point indentation begins by first placing the reference probe on the 
surface of the material to be indented.  This locates the site of the test by constraining the 
test probe from lateral motion across the surface during the indentation process.  The test 
probe repetitively indents the material with a specified number of cyclic indents. Each 
indentation involves slightly deeper penetration of the probe in the test surface compared 
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to the previous indent.  Transducers in the measurement head record test probe 
displacement and indentation force throughout this process as the tip of the probe moves 
within and relative to the surface of the material being indented. 
Based upon this set of repetitive indentations and continuous measurement of 
probe force and accompanying displacement, the test system calculates nine material 
property relevant parameters based on the time dependent force versus indentation probe 
displacement.  These nine material property relevant parameters are:  
1. First cycle indentation distance (ID1st).  
2. Total indentation distance (TID) 
3. Indentation distance increase (IDI) 
4. First cycle creep indentation distance (CID1st)  
5. Average creep indentation distance (AvgCID) 
6. Average loading slope (AvgLS) 
7. Average unloading slope (AvgUS) 
8. First cycle unloading slope (US1st) 
9. Energy dissipation (ED) 
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1.7.1 Indentation Depth Parameters (Parameters 1-5) 
Five of these parameters (ID1st, TID, IDI, CID1st, and AvgCID) are obtained from 
test probe force and displacement data (Figure 1.9).  
Table 1.1 RPI Parameters 
Parameter How Derived How Calculated Relevance References 
ID1st 
Probe 
displacement 
After first 
indentation 
cycle 
Reflects 
material 
hardness 
[35] [36] 
TID 
Probe 
displacement 
After last 
indentation 
cycle 
resist crack 
initiation and 
propagation 
[32] [33] 
IDI 
Probe 
displacement 
Difference 
between first 
and last 
indentation 
cycle 
Strength and 
toughness 
[30] [33] [34] 
[35] [36] [37] 
CID1st 
Probe 
displacement 
During constant 
load 
Toughness [38] 
AvgCID 
Probe 
displacement 
During constant 
load 
Toughness [38] 
AvgLS 
Ratio of probe 
displacement 
and force 
During loading 
resistance to 
plastic 
deformation 
[36] 
AvgUS 
Ratio of probe 
displacement 
and force 
During 
unloading 
Strength and 
toughness 
[35] 
US1st 
Ratio of probe 
displacement 
and force 
During 
unloading 
Strength and 
toughness 
[35] 
ED 
Integration of 
force-
displacement 
curve 
Over the entire 
loading cycle 
Toughness [38] 
 
 ID1st is a measure of test probe penetration depth after the first indentation cycle 
and has been associated with material hardness [35] [36].  TID is the total displacement 
of the probe into the substrate after all loading cycles and is related to bone’s ability to 
resist crack initiation and propagation [32] [33].  Changes in TID have been associated 
with changes in: rat vertebrae compressive strength and toughness as well as yield stress 
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and strength in three-point bending of human femora [35] [33].  IDI is the difference 
between the initial and final cycle indentation depths.  Changes in IDI have been 
associated with changes in: a) strength and toughness in three point bending of rat 
femurs, canine ribs, and human femora, and b) strength and toughness in axial 
compression of rat vertebrae [30] [33] [34] [35] [36] [37]. 
Reference point indentation also quantifies two material creep-relevant parameters 
(CID1st and AvgCID) by recording probe displacement while a constant force is 
maintained on the probe (Figure 1.9).  CID1st is the probe displacement during the first 
cycle of constant load.  AvgCID is the average of probe displacement of all constant load 
cycles.  Changes in these creep parameters have been inversely associated with material 
toughness [38].   
 
Figure 1.9 Indentation Depth Measurements 
1.7.2 Loading/Unloading Slope Parameters (Parameters 6-8) 
Three parameters (AvgLS, AvgUS, and US1st) consider the force-displacement 
slope during loading and unloading of the indentation probe force (Figure 1.10).  AvgUS 
considers the ratio of material strain to test probe force during all indentation cycle while 
indentation force is decreasing.  AvgUS has been associated with strength and toughness 
as measured by dynamic compression testing [35].  US1st considers the ratio of material 
12 
 
strain to test probe force during the first indentation cycle.  Although all of these 
unloading slope measurements are not a direct measurement of the sample’s Young’s 
modulus, they are an indication of Young’s modulus [35].  The average unloading slope 
parameter is able to detect differences between longitudinal and transverse indentations 
of cortical bone. [36].  AvgLS is similar to average unloading slope but considers the 
time periods when the test probe force is increasing.  It is related to bone’s resistance to 
plastic deformation [36].  AvgLS, AvgUS, and US1st values are calculated (Equations 3-
5) using values from the force-displacement graph (Figure 1.10).   
 
Equation 3: AvgLS Calculation 
 
Equation 4: AvgUS Calculation 
 
Equation 5: US1st Calculation 
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Figure 1.10 Loading and Unloading Slope of Example Materials A and B 
1.7.3 Energy Dissipation Parameter (Parameter 9) 
Unrecoverable material deformation after indentation is reflected by the energy 
dissipation (ED) parameter.  This parameter is defined by the area bounded by the load 
and unload curve of the force-displacement relationship (Figure 1.10).  This parameter is 
related to material toughness [33].   
 
Figure 1.11 Reference Point Indentation Dissipated Energy  
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1.8 RPI Testing of Bisphosphonate Treated Cortical Bone 
Several studies have investigated the effects of bisphosphonate treatment and the 
resulting changes in cortical bone RPI parameters.  Arefa et al. treated beagles with 
raloxifene for 6 months to measure changes in their bone material properties [34].  RPI 
testing of the anterior tibial mid shaft surfaces of these beagles was performed using 12 
beagles while another 12 were controls that received oral saline only.  IDI and ED were 
approximately 15% less in the treated beagles compared to the control beagles [34].  A 
related study by Gallant et al. found that healthy beagles treated with bisphosphonates for 
three years resulted in an approximate 17% increase in cortical rib IDI compared to 
untreated control beagles [35].  The observed differences in IDI parameters between 
these two studies may be due to the difference (6 months compared to 3 years) in 
treatment duration.   
Human anterior mid-tibial cortical surfaces were indented by Güerri-Fernández et 
al. using an early prototype reference point indentation system to investigate differences 
between patients with: a) atypical femoral fractures treated with bisphosphonates (AFF), 
b) typical osteoporotic fractures and no BP treatment, c) no fractures with long-term (5 to 
12 years) bisphosphonate use, and d) no fractures and no treatment [30].  TID and IDI in 
patients with atypical femoral fractures treated with bisphosphonates were approximately 
25% greater compared to osteoporotic patients with no fractures and no treatment [30].   
1.9 RPI and Trabecular Bone 
All previous studies that applied microindentation test methods to osseous tissue 
examined cortical bone exclusively.  Application of RPI to trabecular bone is technically 
challenging due to: limited available surface area of trabeculae relative to probe size, 
depth of indentation relative to trabeculae depth, and accuracy/precision of indentation 
probe tip placement on trabeculae.  If RPI can be used to quantify the indentation relevant 
material parameters of trabecular human bone, then additional studies must be conducted 
to determine accuracy and precision within trabeculae and subjects, as well as intra and 
inter observer variability. 
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1.10 Objectives 
The objectives of this study were to: 1) determine if RPI use for trabecular bone is 
feasible and if so, to then determine an optimized test method for using RPI on trabecular 
bone, and 2) use this optimized method for quantifying the RPI parameters of human 
trabecular bone treated with BPs for varying durations.  
2 Microindentation Testing of Human Trabecular Bone 
2.1 Objective 
The previously noted challenges attending application of RPI to trabecular bone 
formed the basis for the first portion of the present research effort.  Use of RPI in 
trabecular bone must be proven feasible by determining whether accurate and precise 
probe placement and RPI measurements can be made in this bone compartment.  
2.2 Theoretical Indentation Depth and Separation Determination 
2.2.1 Strain Field Propagation 
The purpose of the finite element model was twofold; to determine if the strain and 
stress field produced by an indentation depth of 50 microns could be confined to the 
dimensions of a trabeculum and to determine the minimum separation between indents 
without strain field interference.  The volume of trabecular bone permanently altered by 
an indentation using RPI is primarily influenced by the probe size and indentation force.  
While probe size is fixed, increasing probe indentation force increases the indentation 
depth.  Increasing the indentation depth reduces measurement uncertainty due to the 
device’s linear transducer measurement resolution which rounds to the nearest micron.  
Therefore, a measured 50 micron indentation depth could actually be between 49.5 
microns and 50.49̅ microns.  Since all trabecular bone samples are embedded in PMMA, 
an indent larger than the trabecular width or depth would deform the PMMA mounting 
material and result in testing material that was not 100% trabecular bone.  The 
deformation size produced by an indentation can be estimated using finite element 
modeling to determine an optimal indentation force. 
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2.2.2 Indentation Separation  
Minimizing indent separation distance increases the total number of indents 
possible in a sample of limited trabecular surface area. Indent separation distance must be 
large enough to avoid strain field interaction between adjacent indents.  Identification of 
this minimal indentation separation distance can be estimated using finite element 
analysis.   
2.2.3 Finite element method 
Deformation of a simple structure with known material properties caused by an 
applied force can be calculated using standard deformable solid body mechanics.  Finite 
element analysis allows larger, more complex structures to be analyzed in the same 
manner by conjoining a finite number of simple shapes together.  Each simple shape, 
deemed an element, can be represented by a line, triangle, quadrilateral, or any shape 
solvable with partial differential equations.  The deformable solid calculations for these 
numerous elements can be solved simultaneously to determine theoretical stress and 
strain within a complex structure given assumed boundary conditions, deformations, and 
forces acting upon the structure.  This method of using numerous smaller elements to 
analyze a complex deformable solid structure was originally developed by Ray W. 
Clough in 1960 and is known as finite element analysis [39].   
2.2.4 Model Geometry, Constraints, and Properties  
The finite element model for trabecular bone indentation was based upon a single 
body having linear elastic geometry.  The indentation was represented by a force 
distribution. The trabeculum to be indented was assumed to be a simple semi-cylinder 
with the center of indentation placed along the cylindrical axis.  Three planes of 
symmetry were used in this model (Figure 2.1).  The first plane of symmetry was normal 
to the cylindrical axis and placed at varying distances from the center point of 
indentation.  The second plane of symmetry was normal to the cylindrical axis and passed 
through the center point of indentation.  The separation between the first and second 
symmetry planes represented half of the theoretical separation distance between indents.  
The third plane of symmetry was parallel to the cylindrical axis and perpendicular to the 
indentation surface.  This plane of symmetry transforms the semi-cylinder into a quarter- 
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cylinder.  The planes of symmetry are constrained in both X and Z directions.  The 
remaining circumferential surface of the cylinder, representing the boundary with 
PMMA, was assumed to be a fixed support.  The orientations of the three planes are 
shown (Figure 2.1).  The elastic modulus and Poisson’s ratio values used to represent 
trabecular bone were assumed to be 10 GPa and 0.3 [40].  Although bone is a viscoelastic 
material, for purposes of this model it was assumed that bone was linearly elastic, 
isotropic, and homogeneously mineralized.  
 
Figure 2.1 ANSYS Model Symmetry Planes
 
Figure 2.2 ANSYS Variable Load Pressure Indentation Model 
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2.2.5 Material Properties and Indentation Force Modeling 
   The indentation force used in the model was represented by a triangularly shaped 
non-uniform pressure distribution normal to the indentation surface and axisymmetric to 
the center point of indentation (Figure 2.2).  The length of the non-uniform pressure was 
50 microns based on a 90 degree indentation probe tip angle and a target indentation 
depth of 50 microns.  Therefore, the pressure at the edge of the resulting 100 micron 
diameter indent was zero and the pressure at the center of the indent was determined by 
trial and error until the largest deformation in the body was approximately 50 microns.   
 
Figure 2.3 Strain Plot of 200 micron Indent Separation 
 
 
 
 
19 
 
2.2.6 Theoretical Results 
The FEA model of probe indentation into bone was solved using 11 varying center-
to center probe indentation distances ranging from 250 to 125 microns.  Total 
deformation of the structure resulting from the controlled pressure distribution was 
calculated.  The largest deformation determined the indentation depth and this value was 
plotted versus the separation between indents (Figure 2.4).  This plot shows that 
indentation depth increases exponentially when center-to-center indentation distances 
decrease and become less than 175 microns.   
 
Figure 2.4 Indentation Depth versus Indent Separation 
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2.2.7 Theoretical Discussion 
The strain and stress fields propagated in the trabeculum without interacting with 
the lower or edge boundary conditions for the assumed trabeculae size of 280 microns.  
Figure 2.3 shows an indentation depth of 50 microns will not interact with PMMA 
considering the dimensions of this trabecular bone model.  
The device’s transducer measures to the nearest micron.  Therefore if strain field 
interference between two adjacent indents results in a depth variation of less than 1 
micron the device will not detect it.  This occurs if the center-to-center indentation 
distances are greater than 175 microns.  The finite element model used assumed that a 4 
Newton indentation force was used to produce the indentations.  Four N of indentation 
force in preliminary experimental testing using actual human trabecular bone samples 
was the maximum observed indentation force which showed minimal risk for penetrating 
a trabeculum. 
 
Figure 2.5 Indentation Sizes of Different Protocols  
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The limitations of the FEA model used were attributable to assumptions made 
regarding material properties, trabecular shape and size, and indentation force.  Although 
the shape of the modelled trabeculum does not affect propagation of the strain field 
caused by the indentation, provided that the strain field does not extend to the surface of 
the trabeculum.  A vertical axisymmetric pressure distribution does consider force vectors 
and shear forces associated with indentation.  The shape and size of the indent and 
resulting strain field are comparable to the experimental microindentation when only 
considering the effects of indentation separation and depth.  These results were verified 
by the low coefficient of variation seen between adjacent indents separated by 200 
microns in the following section (2.3). 
2.3 Experimental Indentation Protocol and Sample Size Determination 
2.3.1 Maximizing Sample Size 
 Results of the FEA model show that a force of 4 N and a separation of 175 
microns were optimal for reference point indentation of trabecular human bone.  Next, 
the sources of experimental variance needed to be identified and the contributions from 
each estimated so that an optimal RPI testing protocol could be developed.  This protocol 
needed to be as sensitive as possible to allow the relationship between BP treatment 
duration and one or more RPI parameters to be elucidated, if such relationships do in fact 
exist.  Specific testing parameters targeted for optimization included the: number of 
indents per sample, the number of trabeculae tested per sample, and the number of 
samples.  A balance needed to be achieved for the total number of indents per sample so 
that random error could be minimized while maximizing the number of samples with 
adequate trabecular surface area for testing. The estimated random error of each possible 
protocol can be used to determine the optimal indent quantity per location within a 
sample.  The objective of this experimental portion of the study was to determine which 
protocol had the least variance. 
2.3.2 Methods 
Two groups (pre and post-menopausal) of four homogenous ex vivo trabecular 
bone samples from otherwise identical pre and post-menopausal women were obtained.  
Samples consisted of low turnover bone from osteoporotic Caucasian female patients 
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with no history of: bisphosphonate treatment, hormone therapy, cancer, recent smoking, 
steroid use, chronic kidney disease, or diabetes. 55 bone samples matching these criteria 
were obtained.  These samples were prepared for RPI testing and then indented three 
times on each of 3 trabeculum per sample for a total of nine indentations per bone 
sample.   
The results were used to calculate the observed variance between: a) bone samples 
(σb2), b) trabeculae within a bone sample (σt2), and c) indents within a trabeculum (σi2) 
for each RPI parameter by analyzing the variance within each level of the hierarchical 
design.   The observed variances were used to estimate the variance for other candidate 
indentation protocols using Equation 6. 
Equation 6: Estimated Coefficient of Variation for Candidate Protocols 
𝐶𝑉𝑋 =  
𝜎𝐵
𝑁𝐵𝑋
+
𝜎𝑇
𝑁𝐵𝑁𝑇𝑋
+
𝜎𝐼
𝑁𝐵𝑁𝑇𝑁𝐼𝑋
∗ 100 
Where 
𝑋 = Output parameter mean 
σ = Observed variance between indents (𝜎𝐼), trabeculae(𝜎𝑇), and samples (𝜎𝐵) 
N = Number of indents (𝑁𝐼), trabeculae (𝑁𝑇), and biopsies (𝑁𝐵) considered 
  Coefficients of variation for each RPI parameter were averaged so that each 
protocol and sample size could be represented by a single coefficient of variance.  There 
were a total of 14 bone samples treated 10 or more years with bisphosphonates 
constituted the fewest number of samples.  This important subset of the available samples 
formed the basis for determining the experiment that maximized the information from 
these samples and minimized the variance in observed RPI parameters.  These samples 
were collected and visually examined for available cross sectional trabecular area.  Each 
exposed trabeculum on each of these 14 samples was estimated for the number of times it 
could be indented assuming 200 microns of indentation separation and 4 N of indentation 
force.  Quantification of the area in each sample, in units of indentation quantity, allows a 
maximum number of available samples to be identified given a specific indentation 
protocol.  The number of trabeculae in each sample that can be indented given a specific 
number of indents is shown (Table 2.1). 
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2.3.3 Experimental Results 
All candidate indentation protocols, based upon indent allocation and sample size, 
were represented by a single coefficient of variation for each parameter.  The calculated 
coefficient of variances for 5 to 14 bone samples, 1 to 5 trabeculae per sample, and 1 to 4 
indents per trabeculum were plotted MATLAB.  Figure 2.6 shows the coefficient of 
variance for the total indentation depth parameter for each of the combinations.  Each 
possible candidate protocol and its corresponding average coefficient of variation was 
compiled and ranked by variance in  
 
Table 2.2. 
 
 
 
Figure 2.6 Total Indentation Depth Predicted Coefficient of Variation 
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Table 2.1 Possible Indentations in 10+ Year Treated Samples 
# of Trab 
  # of Indents per Trab 
Bone Sample ID Number 4 3 2 1 
B05411 0 1 2 3 
B07507 0 2 3 4 
B10710 2 2 5 5 
B03911 0 2 3 3 
B05610 1 2 6 6 
B02912 0 1 2 2 
B04208 0 1 3 3 
B09111 0 2 5 6 
B04110 1 3 5 5 
B05310 1 3 7 7 
B06110 1 2 4 4 
B03109 2 4 6 6 
B04612 0 0 1 1 
B07010 1 1 4 4 
 
 
Table 2.2 Possible Protocols, Maximum Sample Size, and Coefficient of Variation 
Possible Protocol and Resulting Variation 
Trab Indents Samples Avg C of V 
2 2 13 0.0317 
2 1 13 0.0326 
3 2 11 0.0332 
1 2 14 0.0336 
1 3 13 0.0343 
1 1 14 0.0351 
4 1 9 0.0366 
2 3 9 0.0377 
4 2 8 0.0382 
5 2 6 0.0436 
5 1 6 0.0442 
1 4 7 0.0464 
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2.3.4 Experimental Discussion 
The largest contributor to the observed variance was the number of indented bone 
samples.  The second largest contributor to the observed variance was the number of 
trabeculae indented followed last by the number of indentations on each trabeculum.  The 
degree of contribution for each protocol variable is evident in the three-dimensional plot 
in Figure 2.6.  Increasing the number of indented samples is the most efficient means of 
decreasing random error. 
Variance between samples outweighs variance within the sample because the 
proximity of indents in a single sample.  Indents within a sample are no more than a few 
centimeters apart.  Indents within a trabeculum are measured to a consistent 200 microns 
apart.  Although material properties of bone have been shown to vary in different 
locations of the same bone [41], they are more likely to vary between patients than within 
a sample.  Bone homogenization due to bisphosphonate treatment may reduce this 
variance between treated patients [4] [41].   
2.4 Conclusion 
Reference point indentation using two indents per trabeculae and two trabeculae 
per bone sample offered the lowest calculated CV and was therefore selected for use 
based upon the samples available for examining the relationship between bisphosphonate 
treatment duration and the RPI parameters.  Finite element modeling determined minimal 
indentation separation to be 175 microns to avoid detectable strain field interaction.  
Indentations depths of 50 microns showed no interaction upon the trabecular boundary 
with PMMA.   
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3 RPI of Trabecular Bone with Varying Bisphosphonate Treatment Duration 
3.1 Objectives 
The objective of this study is to determine if any RPI parameters (refer to the list 
cited in section 1.7) are related to the duration of bisphosphonate treatment in human 
trabecular bone by implementing the previously established RPI testing procedure.  
3.2 Methods 
3.2.1 Study Design 
The dependent variable in this cross sectional study was an individual’s duration 
of bisphosphonate treatment in years.  The independent variables were the RPI output 
parameters (section 1.7).  The sample size was expected to be approximately 40.  
Analysis of variance was used to relate each RPI parameter with BP treatment duration.  
Multiple regression analysis was used to consider the following covariates: age, bone 
volume per total volume, bone mineral density, hormone therapy, fracture history, 
exercise, calcium supplement use, and prescription vitamin D use.  This study conforms 
to the Declaration of Helsinki and was approved by the University of Kentucky IRB. 
3.2.2 Inclusion Criteria 
Bone samples were obtained from anterior iliac crest biopsies taken from 
osteoporotic post-menopausal Caucasian female patients between 41-87 years of age who 
had low bone turnover.  These bone samples were catalogued in the Kentucky Bone 
Registry maintained by the University of Kentucky’s Division of Nephrology and 
identified by electronic database. 
3.2.3 Exclusion Criteria 
Samples excluded from patients with: osteogenesis imperfecta, osteomalacia, any 
genetic bone disease, hyperparathyroid disease, chronic kidney disease, Paget’s disease 
of bone, a history of drug or alcohol abuse, a history of smoking, SERM use, steroid use, 
teriparatide treatment, and any medications/disease known to alter bone metabolism.   
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3.2.4 Procedure  
Bone samples in the registry were previously embedded in poly methyl 
methacrylate (PMMA) for processing and preservation.  Embedded bone samples that 
were enrolled in this study were cut to show trabecular cross sections.  Each cross 
sectioned surface was ground and polished flat and smooth using abrasive silicon carbide 
papers of decreasing grit size (ending in 1200 grit). A final polish was achieved using a 
rotating micro cloth wetted with deionized water and suspended diamond particles (0.3-
μm grit size and then 0.05-μm grit size). Samples were placed in an ultrasonic water bath 
for 10 minutes to remove grinding and polishing debris.   
Each sample was clamped in a vice with its polished surface oriented horizontally 
(Figure 3.1).  The sample was visually accessed under a Bausch & Lomb Stereozoom 4 
stereo microscope.  Differentiating areas of PMMA and exposed bone on the surface of 
each sample was difficult due to the polished surface and lack of color contrast.  The 
distinction could only be made when a directional light source was reflected off the 
surface to the observer to better reveal surface texture.  The smooth, polished PMMA 
surface appears glossier than texturized bone tissue as shown in Figure 3.2.   
 
 
Figure 3.1 Trabecular Bone Sample Secured in Vice with V-block Insert 
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Figure 3.2 Trabeculae Identification and Probe Placement 
Placing ink dots on potential indentation sites allowed for more accurate aiming 
of the probe once the sample was in the machine.  While viewed through the stereo 
microscope (Figure 3.2) ink dots of approximately 80 microns diameter were placed on 
trabecular areas of sufficient size to accommodate two indentations set 200 microns or 
more apart.  Two trabeculae from all trabeculae identified as having sufficient available 
test surface area were chosen for indentation at random using a coin flip.  The mounted 
(V-block, Figure 3.1) sample was then placed onto the horizontal test stage of the RPI 
instrument and rotated so that an imaginary line between two potential indents aligned 
with the translational table’s X or Y axis (Figure 3.3).   
 
Figure 3.3 X Y Translation Table for Measuring Indent Separation 
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 The RPI head unit was positioned over and lowered onto the sample surface until 
the RPI device’s scale registered a preload of 530-570 grams.  A maximum indentation 
force of 4 N was used in this study.  Preloading the sample insured that the reference 
probe maintained its XY position on the sample surface during indentation.  After 
indentation, the head unit and indentation probe were raised off the sample surface and 
the sample was moved 200 microns to the next indentation site using a single axis of the 
XY translational table.  The resulting indents are shown in Figure 3.4.  
 
Figure 3.4 Probe Placement and Resulting Indents 
After translating the sample 200 microns the head unit was lowered to a preload 
of 530-570 grams and the second indentation was made.  The procedure was repeated to 
indent the second trabeculum to complete a total of four indents in each sample.  
Indentation validity was defined by the indentation depth, shape of the force vs. 
displacement graph, and visual inspection of the indent. Visual PMMA deformation 
around an indent or a hole in the center of the indented bone tissue is the best indicator of 
an invalid indent (Figure 3.5 Characteristics of an Invalid Indent Results 
Results 
Unusually high indentation depths and low loading slopes displayed by the device 
software (measured values at least 30% different than the average value recorded in each 
sample) may indicate that an indentation involved both PMMA and bone.  This can occur 
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if an indent is too close to the edge of a trabeculum or if a trabeculum has insufficient 
depth or width to sustain an indentation.  Invalid indents were noted in the software and 
excluded from data analysis.   
 
Figure 3.5 Characteristics of an Invalid Indent Results 
3.3 Results 
Of the 58 samples meeting the inclusion criteria, but not the exclusion criteria, 44 
were enrolled in the present study and successfully indented. Samples not indented had 
inadequate exposed surface area or failed accommodate the selected indentation protocol 
given the previously discussed validity criteria.  Samples from bisphosphonate treated 
subjects (0.3 to 14 years) and five samples from untreated osteoporotic subjects were 
indented.   
Indentation distance increase (IDI, section 1.7) (p=0.012), first cycle unloading slope 
(US1st) (p=0.048), and average unloading slope (AvgUS) (p=0.029) were significantly 
correlated with bisphosphonate treatment duration.  When considering the covariates age 
and calcium supplementation use, indentation distance increase (IDI) (p=0.001), total 
indentation depth (TID) (p=0.049), energy dissipated (ED) (p=0.042), first cycle 
unloading slope (US1st) (p=0.028), average unloading slope (AvgUS) (p=0.012), and 
average loading slope (AvgLS) (p=0.049) significantly correlated with bisphosphonate 
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treatment duration.  These RPI parameters were optimally related to subject age, calcium 
supplementation use, and bisphosphonate treatment duration using Equation 7. 
Equation 7: Multivariate Regression Equation  
 
Where, 
𝛽0:   RPI Parameter Intercept 
𝛽𝐴, 𝛽𝐶 , 𝛽𝐷:  Coefficient for Age, Calcium Use, and Treatment Duration 
Age:  Age of Patient in Years 
Calcium: Binary Value for Patient Calcium Supplementation 
BP Duration:  BP Treatment Duration in Years 
  
None of the other 9 RPI parameters (CID, CID1st, and ID1st) were related to 
bisphosphonate treatment duration despite consideration of all listed covariates.  The 
multiple regression equation coefficients for the 6 correlated RPI parameters are shown 
(Table 3.1).  Linear regression plots for each of these 6 equations are provided (Figure 
3.6-Figure 3.11). 
Table 3.1 Multiple Regression Equation Coefficients 
 IDI TID ED US1st AvgUS AvgLS 
𝑏0 4.9070 44.092 11.38855 0.29434 0.29172 0.20779 
𝑏𝐴 -0.00979 -0.03811 -0.01809 0.00026 0.00035 0.00021 
𝑏𝐶 -0.45104 -1.23064 -0.81775 0.00764 0.01001 0.00550 
𝑏𝐷 0.04678 0.10300 0.10206 -0.00136 -0.00158 -0.00080 
 
Table 3.2: p Values for Regression Equation Coefficients  
 IDI TID ED US1st AvgUS AvgLS 
𝑏𝐴 NS NS NS NS NS NS 
𝑏𝐶 0.0017 0.0188 NS NS NS NS 
𝑏𝐷 0.0013 0.0490 0.0423 0.0284 0.0118 0.0485 
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Figure 3.6 Indentation Distance Increase (IDI, µm) vs Bisphosphonate Treatment 
Duration (dur, years) (p=0.0115) (R2=0.34)
 
Figure 3.7 Total Indentation Depth (TID, µm) vs Bisphosphonate Treatment Duration 
(dur, years) (NS) (R2=0.19) 
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Figure 3.8 Energy Dissipated (ED) vs Bisphosphonate Treatment Duration (dur, years) 
(NS) (R2=0.14)
 
Figure 3.9 1st Cycle Unloading Slope (US1st) vs Bisphosphonate Treatment Duration 
(dur, years) (p=0.0481) (R2=0.13) 
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Figure 3.10 Average Unloading Slope (AvgUS) vs Bisphosphonate Treatment Duration 
(dur, years) (p=0.0286) (R2=0.18) 
 
Figure 3.11 Average Loading Slope (AvgLS) vs Bisphosphonate Treatment Duration 
(dur, years) (NS) (R2=0.12) 
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3.3.1 Calcium Supplement Usage 
Subjects who did not report using calcium supplementation were found to follow a 
significantly higher regression slope than those not taking a supplement.  This difference 
between regression slopes was found by testing the interactive relationship between 
variables of calcium supplementation and treatment duration within the multivariate 
regression models for TID and IDI. Figure 3.12 and Figure 3.13 show the differences in 
regression slope with (35 patients) and without (7 patients) calcium supplementation for 
TID and IDI.   
 
 
 
Figure 3.12 IDI vs Treatment Duration Considering Calcium Usage 
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Figure 3.13  TID vs Treatment Duration Considering Calcium Usage 
 
3.4 Discussion 
RPI parameters can be sorted into to two categories based upon how the parameter 
is calculated.  All RPI parameters are calculated by measuring either test probe 
displacement (indentation depth parameters) or the relationship between force and test 
probe displacement (loading/unloading slope parameters).  Both of these categories 
include RPI parameters which were shown by the results of the present study to be 
significantly correlated with bisphosphonate treatment duration.  Because these 
parameters and have also been related to established material properties, the results of the 
present study provide evidence that the material properties of trabecular bone are related 
to bisphosphonate treatment duration.  The three indentation depth parameters correlated 
positively with bisphosphonate treatment length while the three loading/unloading slope 
parameters negatively correlated with bisphosphonate treatment length.  An RPI 
parameter’s significance with bisphosphonate treatment length was found to be generally 
affected by which indentation cycle(s) were used in the calculation of the RPI parameter. 
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3.4.1 Indentation Depth with Increasing Treatment Duration 
The indentation distance between the first indentation cycle and last indentation 
cycle increased with increasing bisphosphonate treatment duration.  A similar trend was 
seen in outputs of ED and TID.  ED is a function of TID and the force applied over time.  
The force produced by the indentation probe is consistent for each indentation, therefore 
ED is directly related to TID due to ED’s calculation method.  This explains similar ED 
and TID p-values (p=0.049 and 0.049 respectively) and multiple regression coefficients 
seen in . 
Table 3.1. 
First cycle indentation depth was the only indentation depth parameter that was 
unrelated to bisphosphonate treatment duration.  The particular locations at which an 
indent was placed may contain varying amounts of physical imperfections such as 
microcracks or surface imperfections.  The 1st cycle indentation depth deforms the most 
bone volume. The calculations for ED and TID take the 1st cycle indentation depth 
measurement into account.  Physical material imperfections may have contributed to the 
higher data variability seen in ED (p=0.049) and TID (p=0.049) compared to another 
indentation depth parameter that doesn’t take 1st cycle indentation depth into account 
(p=0.01 for IDI).  Three of the four RPI indentation parameters (TID, ID1st, IDI, and ED) 
each calculated using indentation depth, showed significant positive relationships with 
bisphosphonate treatment duration.  These parameters reflect changes in the material 
properties of bone associated with varying bisphosphonate treatment duration.   
 
3.4.2 Indentation Depth and Material Properties 
IDI has been shown in other studies to be inversely proportional to yield stress, 
strength, and toughness as measured by traditional destructive mechanical tests [37] [30] 
[35] [36] [33].  Güerri-Fernández et al. found significantly higher TID and IDI in 
fractured, long-term bisphosphonate treated patients compared to osteoporotic control 
patients [30] (Figure 3.14 A and B). 
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Figure 3.14 A & B Results of Güerri-Fernández et al. [30] 
 
Aref et al. studied beagles treated with bisphosphonates for 6 months and found a 
decrease in IDI and ED when indenting beagle ribs compared ribs taken from untreated 
beagles [34].    Discrepancy between the presently observed increases in IDI and ED with 
increasing bisphosphonate treatment duration in human bone and the decreased IDI and 
ED observed in beagles following 6 months of bisphosphonate treatment may be due to 
the single brief treatment duration of the beagle study compared to the lengthy (0.3 to 14 
years) treatment durations used in the present study.   
 
Figure 3.15 Comparing control (VEH) and BP treated (RAL) beagle by Aref et al. [34] 
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Nogués et al. used a similar RPI device which outputs a different parameter than 
the RPI device in the present study [42].  Nevertheless, Nogués et al. found a significant 
decrease in the bone material strength index, the single output parameter of their RPI 
device, in 40 long-term treated patients treated with bisphosphonates for 4-14 years [42].  
Gallant et al. found that healthy beagles treated with bisphosphonates for three years 
showed a significant increase in cortical rib IDI compared to untreated control beagles 
(Figure 3.16) [35].  Gallant et al. also was able to correlate their IDI results to bone 
toughness as measured by three-point bending testing of excised beagle ribs [35].   
 
Figure 3.16 Results of Gallant et al. [35] 
3.4.3 Loading/Unloading Slope with Increasing Treatment Duration 
The present study showed that RPI parameters involving loading and unloading 
portions of the force-depth indentation cycle were related to bisphosphonate treatment 
duration.  Multiple regression models relating AvgUS, US1st, and AvgLS to treatment 
duration, following the inclusion of age and calcium supplementation as covariates, all 
showed negative slopes in the expressions relating the dependent variable (RPI 
parameters) to the independent variable (treatment duration).  Unloading slope, not 
loading slope, is traditionally used in other indentation methods to calculate elastic 
modulus of a material [22] [23].  Like the RPI indentation depth measurements, the 
loading/unloading slope output parameters of the RPI device are indications of well-
established material properties. 
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3.4.4 Loading/Unloading Slope and Material properties   
Gallant et al. found significantly lower values of US1st in diabetic rat femurs and 
vertebrae compared to a nondiabetic control group [35].  US1st has been associated with 
material properties derived from rat vertebral axial compression testing such as toughness 
and modulus [35].    
3.4.5 Correlated RPI Parameters and Trabecular Bone Mechanical Properties 
Studies comparing RPI parameters to traditional mechanical properties the idea 
that increases in IDI, TID, and ED and decreases in AvgUS, US1st, and AvgLS indicate a 
decrease in a material’s yield stress, strength, and toughness.  The presently observed 
increases in IDI, TID, and ED with increasing BP treatment duration indicate a decline in 
the material properties of trabecular bone with increasing bisphosphonate treatment 
duration.  If loading and unloading slope RPI parameters (AvgUS, US1st, and AvgLS) 
are in fact indicators of modulus and toughness, as found by Gallant et al., then the 
present study’s results show a decline in trabecular bone modulus and toughness with 
increasing bisphosphonate treatment.   
3.5 Uncorrelated RPI Parameters 
Three parameters (CID, CID1st, and ID1st) were uncorrelated with 
bisphosphonate treatment duration.  Two of these parameters, CID and CID1st, are creep-
related and measure changes in probe displacement during constant load application.  
This lack of significance may be a result of the selected device loading frequency of 2 
Hertz and bone sample preparation.  Dehydrated bone is known to have decreased 
viscoelastic properties, increased material modulus, and increased microhardness as 
measured by nanoindentation [43].  Creep related RPI measurements are less sensitive in 
dry bone and thus less able to detect changes associated with bisphosphonate duration.  
The length of time in which a constant force is applied before the device takes a creep-
related RPI measurement is short.  Specifically, the present study used an indentation 
frequency of 2 Hz resulting in a constant force being applied to the sample for 0.167 
seconds for each indentation cycle as shown in Figure 3.17.  Other nanoindentation 
studies using dehydrated cortical bone apply constant load loading for 30 to 60 seconds to 
measure material creep properties accurately [50] [44] [45].  Relatively short loading 
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durations from the RPI device, and the use of dehydrated bone samples, decreased the 
magnitude of RPI creep parameters to the extent that RPI creep parameter magnitudes 
were comparable in size to the measurement uncertainty of the RPI device.  This 
similarity reduced the likelihood of detecting a significant correlation.  
The remaining RPI parameter, 1st cycle indentation depth (ID1st), was unrelated 
to BP treatment duration even when considering patient age and calcium supplementation 
as covariates (p=0.088).  The ID1st parameter is directly affected by physical 
imperfections in the volume of bone it deforms.  The initial indentation produces the 
largest plastic deformation of all cycles (Figure 3.18 and Figure 3.19).  Therefore first 
cycle indentation depth is the RPI parameter most likely to be affected by material 
variances within a volume.  Even though many of these imperfections are on the level of 
nanometers, altering TID a single micron is a 2.2-3.8% measurement variation.  For 
comparison, a study by Granke, et al. found the variation for TID on a homogeneous, 
calibrated surface to be 0.8% [36].   
 
Figure 3.17 Force-Time Graph of a 4 N 5 Cycle Indent at 2 Hz 
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Figure 3.18 Indentation Distance per Cycle 
 
Figure 3.19 Distance-Time Graph of a 4 N, 5 Cycle, and 2 Hz RPI 
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Figure 3.20 Force-Distance Graph of a 4 N, 5 Cycle, and 2 Hz RPI 
3.5.1 Calcium Supplement Usage 
Subjects who did not report use of calcium supplements showed greater rates of 
change in IDI and TID with bisphosphonate treatment duration compared to subjects who 
reported use of calcium supplements.  A rigorous comparison cannot be made between 
these two populations because the number of patients in the present study not taking a 
calcium supplement (7 patients) is substantially less than patients who did (35 patients).  
The increased TID and IDI slopes of bisphosphonate treated individuals not taking a 
calcium supplement indicates an accelerated decrease in trabecular bone yield stress, 
strength, and toughness versus bisphosphonate treated patients taking a calcium 
supplement [13].  Alternatively, decreased TID and IDI slopes of bisphosphonate treated 
individuals taking a calcium supplement may indicate that calcium supplementation 
decreases the rate at which trabecular bone yield stress, strength, and toughness 
deteriorates versus bisphosphonate treated patients not taking a calcium supplement [13].  
It is also possible that patients not taking a calcium supplement have a higher likelihood 
of noncompliant bisphosphonate usage which would result in an accelerated decrease in 
trabecular bone property compared to compliant patients [13]. 
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3.5.2 Limitations  
The linear regression of all BioDent parameters with treatment duration showed a 
low R-Square value despite significant p values.  There is an inherently high variability 
between samples based upon unknown contributing factors inherent to cross sectional 
studies. 
Bone biopsies selected for this test were all supplied by the University of Kentucky 
Division of Nephrology bone library.  The inclusion and exclusion criteria used to select 
samples were based on available patient information. Patient information was not 
comprehensive and some data remain unknown.  For example, a patient may have 
claimed to have exercised regularly but the degree and type of exercise was not noted.  
Accuracy of patient reported information is not assured and no guarantees exist that 
patients were completely compliant with their BP treatment.   
The shape and size of the substrate beneath the exposed surface of the biopsy was 
unknown for each indent.  Indentations with visual abnormalities or measurements 
resembling PMMA were discarded as discussed in section 3.2.4.  It is possible that 
indents partially interacting with PMMA because of insufficient substrate volume were 
analyzed in the results.   
4 Conclusions 
4.1 Reference Point Indentation of Trabecular Bone 
Reference point indentation can be successfully used to quantify relevant material 
parameters of trabecular human bone.  The protocol developed for RPI study of such 
bone, i.e., indents of 4 N and 5 cycles applied to two indentation sites in each of two 
randomly chosen trabeculae per each bone sample, was proven feasible and minimizes 
data variability when applied to large numbers of bone samples obtained from a diverse 
patient population. 
4.2 Relevance of Material Property Changes in Trabecular Bone 
 Increasing bisphosphonate treatment duration is associated with reductions in 
trabecular bone modulus, yield stress, strength, and toughness as reflected by RPI related 
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parameters.  The relevance of these RPI parameters to well established material 
parameters of modulus, yield stress, strength, and toughness are supported by previously 
published studies.  RPI’s ability to indicate material parameters changes may offer new 
opportunities for treatment monitoring.  These opportunities may lead to new guidelines 
for bisphosphonate treatment discontinuance or to assess the effectiveness of other 
treatment options to change bone material properties and subsequently the mechanical 
load bearing competence of bone.   
4.3 Future Directions 
4.3.1 Calcium Supplementation  
Comparatively higher rates of increase in IDI and TID in patients not reportedly 
taking calcium supplements during bisphosphonate treatment indicates that this treatment 
group experienced a higher rate of material property deterioration compared to those 
taking a calcium supplement as discussed in section 3.5.1.  Patients in this study who 
reported taking calcium supplements were observed to have comparatively lower rates of 
trabecular bone material property deterioration with increasing bisphosphonate treatment 
duration as indicated by TID and IDI.  Alternatively, it could be inferred that patients 
who use a calcium supplement take greater personal responsibility for their bone health 
and are more compliant with their bisphosphonate treatment and thus have more 
favorable trabecular bone material properties, as indicated by RPI parameters, because 
bisphosphonates are efficacious when taken as prescribed.  Evaluation of this hypothesis 
awaits further study. A larger cross sectional study may provide some clarifying 
information that helps reduce data variations due to possible patient noncompliance.     
4.3.2 Nanoindentation Comparison 
Reference point indentation parameters are relatively unproven in comparison to 
established material parameters such as Young’s modulus, yield point, strength, etc. that 
are obtained from conventional destructive material testing.  All bone samples indented 
with the RPI device in the present study have also been indented using a Nanoindenter 
XP (MTS Nano Instruments, Oak Ridge, TN) to measure Young’s modulus and 
microhardness.  The usefulness of one or more of the nine studied RPI parameters will be 
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strengthened if correlations are observed between one or more of these parameters and 
Young’s modulus or hardness as measured by nanoindentation.  
4.3.3 Cortical Bone RPI 
The first objective of this study was to pioneer the use of RPI within trabecular bone.  
Some trabecular bone biopsies indented in the present study also contain cortical bone 
suitable for reference point indentation.  Taking RPI measurements of this cortical bone 
despite its small sample size is merited given the successful technique development and 
significant correlations between 6 of 9 RPI parameters and varying bisphosphonate 
treatment.  Comparisons between the RPI parameters of different mineralized tissue types 
(cortical and trabecular) within the same sample could be investigated.   
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Appendices 
Appendix A: SAS Output  
 
The SAS System 
 
The GLM Procedure 
  
Dependent Variable: m_IDI IDI 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 2.41449600 0.80483200 6.97 0.0007 
Error 40 4.62202389 0.11555060     
Corrected Total 43 7.03651989       
 
R-Square Coeff Var Root MSE m_IDI Mean 
0.343138 8.098986 0.339927 4.197159 
 
Source DF Type I SS Mean Square F Value Pr > F 
age 1 0.00425422 0.00425422 0.04 0.8488 
calcium 1 1.03566425 1.03566425 8.96 0.0047 
dur 1 1.37457753 1.37457753 11.90 0.0013 
 
Source DF Type III SS Mean Square F Value Pr > F 
age 1 0.22529821 0.22529821 1.95 0.1703 
calcium 1 1.30151527 1.30151527 11.26 0.0017 
dur 1 1.37457753 1.37457753 11.90 0.0013 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 4.906973072 0.44891197 10.93 <.0001 
age -0.009797848 0.00701678 -1.40 0.1703 
calcium -0.451042684 0.13439376 -3.36 0.0017 
dur 0.046788057 0.01356552 3.45 0.0013 
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The SAS System 
 
The GLM Procedure 
  
Dependent Variable: m_AvgLS AvgLS 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 0.00056166 0.00018722 1.90 0.1456 
Error 40 0.00394800 0.00009870     
Corrected Total 43 0.00450966       
 
R-Square Coeff Var Root MSE m_AvgLS Mean 
0.124545 4.499545 0.009935 0.220795 
 
Source DF Type I SS Mean Square F Value Pr > F 
age 1 0.00001499 0.00001499 0.15 0.6988 
calcium 1 0.00013786 0.00013786 1.40 0.2442 
dur 1 0.00040880 0.00040880 4.14 0.0485 
 
Source DF Type III SS Mean Square F Value Pr > F 
age 1 0.00010495 0.00010495 1.06 0.3087 
calcium 1 0.00019324 0.00019324 1.96 0.1695 
dur 1 0.00040880 0.00040880 4.14 0.0485 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 0.2077937786 0.01312000 15.84 <.0001 
age 0.0002114664 0.00020507 1.03 0.3087 
calcium 0.0054959110 0.00392782 1.40 0.1695 
dur -.0008068786 0.00039647 -2.04 0.0485 
 
49 
 
 
The SAS System 
 
The GLM Procedure 
  
Dependent Variable: m_TID TID 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 15.59834135 5.19944712 3.22 0.0328 
Error 40 64.66728365 1.61668209     
Corrected Total 43 80.26562500       
 
R-Square Coeff Var Root MSE m_TID Mean 
0.194334 3.077732 1.271488 41.31250 
 
Source DF Type I SS Mean Square F Value Pr > F 
age 1 0.84049497 0.84049497 0.52 0.4751 
calcium 1 8.09556885 8.09556885 5.01 0.0309 
dur 1 6.66227752 6.66227752 4.12 0.0490 
 
Source DF Type III SS Mean Square F Value Pr > F 
age 1 3.40899190 3.40899190 2.11 0.1543 
calcium 1 9.68907319 9.68907319 5.99 0.0188 
dur 1 6.66227752 6.66227752 4.12 0.0490 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 44.09260007 1.67914191 26.26 <.0001 
age -0.03811227 0.02624606 -1.45 0.1543 
calcium -1.23064879 0.50269588 -2.45 0.0188 
dur 0.10300582 0.05074143 2.03 0.0490 
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The SAS System 
 
The GLM Procedure 
  
Dependent Variable: m_ED ED 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 9.77007515 3.25669172 2.19 0.1041 
Error 40 59.45110383 1.48627760     
Corrected Total 43 69.22117898       
 
R-Square Coeff Var Root MSE m_ED Mean 
0.141143 11.97694 1.219130 10.17898 
 
Source DF Type I SS Mean Square F Value Pr > F 
age 1 0.00040943 0.00040943 0.00 0.9868 
calcium 1 3.22969821 3.22969821 2.17 0.1483 
dur 1 6.53996751 6.53996751 4.40 0.0423 
 
Source DF Type III SS Mean Square F Value Pr > F 
age 1 0.76817953 0.76817953 0.52 0.4764 
calcium 1 4.27814259 4.27814259 2.88 0.0975 
dur 1 6.53996751 6.53996751 4.40 0.0423 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 11.38855347 1.60999695 7.07 <.0001 
age -0.01809186 0.02516528 -0.72 0.4764 
calcium -0.81775016 0.48199549 -1.70 0.0975 
dur 0.10205592 0.04865196 2.10 0.0423 
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The SAS System 
 
The GLM Procedure 
  
Dependent Variable: m_AvgUS AvgUS 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 0.00203197 0.00067732 3.01 0.0412 
Error 40 0.00899303 0.00022483     
Corrected Total 43 0.01102500       
 
R-Square Coeff Var Root MSE m_AvgUS Mean 
0.184305 4.798141 0.014994 0.312500 
 
Source DF Type I SS Mean Square F Value Pr > F 
age 1 0.00001984 0.00001984 0.09 0.7680 
calcium 1 0.00044477 0.00044477 1.98 0.1673 
dur 1 0.00156736 0.00156736 6.97 0.0118 
 
Source DF Type III SS Mean Square F Value Pr > F 
age 1 0.00028469 0.00028469 1.27 0.2672 
calcium 1 0.00064158 0.00064158 2.85 0.0989 
dur 1 0.00156736 0.00156736 6.97 0.0118 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 0.2917207094 0.01980150 14.73 <.0001 
age 0.0003482896 0.00030951 1.13 0.2672 
calcium 0.0100142836 0.00592811 1.69 0.0989 
dur -.0015799204 0.00059838 -2.64 0.0118 
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The SAS System 
 
The GLM Procedure 
  
Dependent Variable: m_US1st US1st 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 0.00141269 0.00047090 2.09 0.1161 
Error 40 0.00899129 0.00022478     
Corrected Total 43 0.01040398       
 
R-Square Coeff Var Root MSE m_US1st Mean 
0.135784 4.852376 0.014993 0.308977 
 
Source DF Type I SS Mean Square F Value Pr > F 
age 1 0.00000435 0.00000435 0.02 0.8901 
calcium 1 0.00024540 0.00024540 1.09 0.3024 
dur 1 0.00116294 0.00116294 5.17 0.0284 
 
Source DF Type III SS Mean Square F Value Pr > F 
age 1 0.00015893 0.00015893 0.71 0.4054 
calcium 1 0.00037375 0.00037375 1.66 0.2046 
dur 1 0.00116294 0.00116294 5.17 0.0284 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 0.2943424440 0.01979958 14.87 <.0001 
age 0.0002602301 0.00030948 0.84 0.4054 
calcium 0.0076433972 0.00592753 1.29 0.2046 
dur -.0013609105 0.00059832 -2.27 0.0284 
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